SPECIAL NOTICE
We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
23 January 2022
| Name: | MEDIBIO LIMITED (MEB) | ||||||
| ISIN: | AU000000MEB8 | ||||||
| Date of Listing: | 29 January 2001 | ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 008 130 336ABN: 58 008 130 336
Registration Date: 05 March 1987
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| MEDIBIO LIMITED | 01/12/2014 | |
| BIOPROSPECT LIMITED | 01/12/2014 |
Computershare Investor Services, Level 11 172 St Georges Terrace Perth WA 6000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)Expand this box to read and print
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising. | 10/07/2019 |
Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019. | 10/07/2019 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 09/07/2019 |
we understand that on or about this date the company consolidated its shares 1 for 100 | 20/03/2015 |
The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB | 01/12/2014 |
name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99. | 01/12/2014 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising. | 10/07/2019 |
Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019. | 10/07/2019 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 09/07/2019 |
we understand that on or about this date the company consolidated its shares 1 for 100 | 20/03/2015 |
The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB | 01/12/2014 |
name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99. | 01/12/2014 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 09/11/2018 | Chris Indermaur | 200,000 | $0.040 | $8,000 |
| 06/11/2018 | Andrew Maxwell | 216,002 | $0.044 | $9,434 |
| 02/08/2017 | Andrew Maxwell | 26,000 | $0.380 | $9,880 |
| 10/07/2017 | Peter Carlisle | 5,500 | $0.373 | $2,053 |
| 18/04/2017 | Jack Cosentino | 100,000 | $0.370 | $37,000 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Claude Solitario | Managing Director | 29/04/2014 |
| Steve Sathre | CFO | 01/01/2019 |
| Peter Carlisle | Independent Director | 05/06/2017 |
| Lisa Heine | Non Exec Director | 29/08/2019 |
| Lisa Ide | Non Exec Director | 29/08/2019 |
| Liwanag Ojala | Non Exec Director | 29/08/2019 |
| Melanie Leydin | Non Exec Director | 22/02/2019 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| David Kaysen | Chairman, CEO | 02/11/2018 | 08/01/2020 |
| Franklyn Prendergast | Non Exec Director | 27/01/2016 | 29/08/2019 |
| Michael Phelps | Non Exec Director | 05/06/2017 | 29/08/2019 |
| Patrick Kennedy | Non Exec Director | 04/07/2017 | 29/08/2019 |
| Andrew Maxwell | Non Exec Director | 01/02/2017 | 22/02/2019 |
| Brian Mower | CFO | 24/04/2017 | 01/01/2019 |
| Chris Indermaur | Non Exec Chairman | 02/04/2015 | 31/12/2018 |
| Jack Cosentino | Managing Director, CEO | 16/02/2017 | 28/08/2018 |
| Adam Darkins | Deputy Chairman, Non Exec Director | 19/07/2017 | 19/01/2018 |
| Kris Knauer | Executive Director, CFO | 02/07/2014 | 13/10/2017 |
| Robert Lees | CFO | 28/09/2012 | 24/04/2017 |
| James Campbell | Non Exec Director | 07/09/2014 | 30/09/2016 |
| Vince Fayad | Non Exec Chairman | 29/04/2014 | 07/04/2015 |
| Silvi Elkhouri | Non Exec Director | 15/11/2013 | 08/09/2014 |
| Claude Solitario | Executive Director | 29/04/2014 | 08/09/2014 |
| Peter May | Non Exec Director | 01/11/2008 | 30/06/2014 |
| Benjamin Cooper | Executive Director | 10/04/2012 | 29/04/2014 |
| Winton Willesee | Chairman, Non Exec Director | 16/09/2011 | 15/11/2013 |
| Peter Pellegrino | Managing Director | 01/11/2009 | 19/11/2012 |
| Colin Johnston | CFO | 01/03/2004 | 28/09/2012 |
| Jacob Khouri | Non Exec Director | 16/02/2011 | 18/09/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2022 Investogain Pty Limited. All rights reserved.
